Search results
POTS-associated Conditions and Management Strategies
Video Series
Author(s):
Milind Y Desai
Added:
1 year ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more
Author(s):
Harriette Van Spall
,
Isabelle Mahé
Added:
1 year ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the…
View more
Shaun R Opie
Research Area(s) / Expertise:
Author
Expertise
Duvuru Geetha
Research Area(s) / Expertise:
Job title: Professor of Nephrology, Johns Hopkins University School of Medicine, Baltimore, US
Author
Susanne Bechtold
Job title: Consultant Paediatric Endocrinologist and Diabetologist
Author
Francesco Saia
Job title: Interventional cardiologist
Author